Business Wire

THALES

12.6.2019 07:02:08 CEST | Business Wire | Press release

Share
Gemalto Identity Management System to Empower the World’s Citizens with Secure and Unique Identities

Gemalto, a Thales company, is launching its Identity Management System (IDMS) that can help governments address the challenges posed by a world in which over one billion people have no official ID. Using the latest biometric capture and identity verification techniques, Gemalto’s solutions enable public authorities to empower citizens with a fully secured and trusted Foundational Identity. This system supports people identification and authentication so they can securely access online and offline services such as education or healthcare, and proves their right to participate in elections, apply for a passport or open a bank account. Users retain full control over their personal data, choosing how and when it is shared with service providers.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190611005462/en/

UN targets universal provision of ID by 2030

The staggering number of citizens rendered invisible to public agencies by the absence of an official ID includes one out of three children worldwide. Most international financial institutions are supporting Digital ID schemes in many countries over the next ten years. These initiatives are also backed by the UN, which has itself set the target of everyone on the planet having a legal identity by 20301 .

Mobile, biometric-based registration can reach remote and isolated areas

Gemalto’s IDMS provides authorities with a fully integrated, end-to-end solution which can adapt to existing identity schemes and orchestrate its interactions. The process starts with registration of a person and capture of their biometrics, with easy-to use mobile technology ensuring coverage can reach even the most remote regions. Registration is followed by entry onto a central database or civil registry and the creation of a unique individual identifier.

Reaping the benefits of Foundational ID

This Foundational Identity can provide the basis for issuance of digital and physical ID credentials, and subsequent registration with numerous different public bodies and services. All these processes can be verified beyond doubt using the individual’s biometrics and unique identifier. Gemalto’s approach also offers citizens outstanding protection, and assurance that their data will not be used for commercial gain.

Promoting inclusion, fighting fraud

For governments, a universal ID program facilitates accurate planning of public services, and comprehensive social inclusion strategies. Robust protection against the threat of fraud is also provided, as part of the digital ID platform to further boost efficiency, convenience and adoption of eServices. The Foundational Identity also eliminates the need for individual bodies, such as those responsible for health and welfare, to continually repeat enrollment procedures.

“A unique legal ID is a basic human right that can unlock access to many more – including education, welfare and participation in the democratic process,” said Frédéric Trojani, senior vice president Identity and Biometric Solutions for Thales . “Our Identity Management System leverages unrivalled experience in delivering Digital Identity solutions that empower citizens, defend their personal data, and ensure unhindered access to the rights and services.”

Note to editors

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. Gemalto’s technologies and services authenticate people, transactions and objects, encrypt data and create value for software – enabling businesses and governments to deliver secure digital services for billions of individuals and things.

About Thales

The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. With 80,000 employees in 68 countries, Thales reported sales of €19 billion in 2018.

PLEASE VISIT

Thales Group
Digital Security
Download HD photos

1 UN Sustainable Development Goal (SDG) 16.9

Contact:

PRESS Thales, Media Relations Security Constance Arnoux +33 (0)6 44 12 16 35 constance.arnoux@thalesgroup.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye